Breakthrough Alzheimer's Drug Targets Key Tau Protein Hotspots

Researchers develop RI-AG03, a promising drug that inhibits Tau protein aggregation, potentially paving the way for more effective Alzheimer's treatments.

RI-AG03 is the first drug to target both major aggregation-promoting hotspots of the Tau protein, crucial in Alzheimer's disease.
The drug has shown effectiveness in preventing Tau protein build-up in laboratory and fruit fly studies.
Researchers observed that RI-AG03 extended the lifespan of fruit flies with pathogenic Tau by about two weeks.
The drug reduced Tau aggregation in human cell lines, indicating potential beyond fruit fly models.
RI-AG03 will undergo further testing in rodents before potential clinical trials, with hopes for fewer side effects than current treatments.